Boston Scientific: Oversold, Litigated, but Set Up for a Tactical Recovery (Rating Upgrade)
Boston Scientific (BSX) is under pressure after a sharp earnings-driven selloff and multiple securities class action filings, but technical oversold conditions, a healthy free cash flow profile ($3.66B), and manageable leverage argue for a measured tactical long. This is a rated-up trade idea: enter around $68.60, stop at $64.00, and target $82.00 …